0 false false false false false false false false false true false false false false false false No description of principal activity 2022-07-01 Sage Accounts Production Advanced 2021 - FRS102_2021 xbrli:pure xbrli:shares iso4217:GBP 12036798 2022-07-01 2023-06-30 12036798 2023-06-30 12036798 2022-06-30 12036798 2021-07-01 2022-06-30 12036798 2022-06-30 12036798 core:LandBuildings core:LongLeaseholdAssets 2022-07-01 2023-06-30 12036798 bus:OrdinaryShareClass1 2022-07-01 2023-06-30 12036798 bus:Director1 2022-07-01 2023-06-30 12036798 core:WithinOneYear 2023-06-30 12036798 core:WithinOneYear 2022-06-30 12036798 core:LandBuildings core:LongLeaseholdAssets 2022-06-30 12036798 core:LandBuildings core:LongLeaseholdAssets 2023-06-30 12036798 core:ShareCapital 2023-06-30 12036798 core:ShareCapital 2022-06-30 12036798 core:RetainedEarningsAccumulatedLosses 2023-06-30 12036798 core:RetainedEarningsAccumulatedLosses 2022-06-30 12036798 core:LandBuildings core:LongLeaseholdAssets 2022-06-30 12036798 bus:SmallEntities 2022-07-01 2023-06-30 12036798 bus:AuditExemptWithAccountantsReport 2022-07-01 2023-06-30 12036798 bus:FullAccounts 2022-07-01 2023-06-30 12036798 bus:SmallCompaniesRegimeForAccounts 2022-07-01 2023-06-30 12036798 bus:PrivateLimitedCompanyLtd 2022-07-01 2023-06-30 12036798 bus:OrdinaryShareClass1 2023-06-30 12036798 bus:OrdinaryShareClass1 2022-06-30 12036798 core:ComputerEquipment 2022-07-01 2023-06-30 12036798 core:ComputerEquipment 2023-06-30
COMPANY REGISTRATION NUMBER: 12036798
SRA MEDICAL LIMITED
FILLETED UNAUDITED FINANCIAL STATEMENTS
30 June 2023
SRA MEDICAL LIMITED
FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2023
Contents
Pages
Balance sheet 1
Notes to the financial statements 2 to 4
SRA MEDICAL LIMITED
BALANCE SHEET
30 June 2023
2023
2022
Note
£
£
Fixed assets
Tangible assets
4
70,019
76,650
Current assets
Debtors
5
27,800
Cash at bank and in hand
177,188
79,849
-------------
-------------
177,188
107,649
Creditors: amounts falling due within one year
6
( 21,356)
( 19,092)
-------------
-------------
Net current assets
155,832
88,557
-------------
-------------
Total assets less current liabilities
225,851
165,207
-------------
-------------
Net assets
225,851
165,207
-------------
-------------
Capital and reserves
Called up share capital
7
2
2
Profit and loss account
225,849
165,205
-------------
-------------
Shareholders funds
225,851
165,207
-------------
-------------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the profit and loss account has not been delivered.
For the year ending 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 16 February 2024 , and are signed on behalf of the board by:
S Rasakumaran
Director
Company registration number: 12036798
SRA MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2023
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 36 Lightridge Road, Huddersfield, HD2 2HF.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Leasehold improvements
-
10% straight line
Equipment
-
33% straight line
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
4. Tangible assets
Leasehold improvements
Equipment
Total
£
£
£
Cost
At 1 July 2022
85,167
85,167
Additions
756
1,808
2,564
-------------
-------------
-------------
At 30 June 2023
85,923
1,808
87,731
-------------
-------------
-------------
Depreciation
At 1 July 2022
8,517
8,517
Charge for the year
8,592
603
9,195
-------------
-------------
-------------
At 30 June 2023
17,109
603
17,712
-------------
-------------
-------------
Carrying amount
At 30 June 2023
68,814
1,205
70,019
-------------
-------------
-------------
At 30 June 2022
76,650
76,650
-------------
-------------
-------------
5. Debtors
2023
2022
£
£
Trade debtors
27,800
-------------
-------------
6. Creditors: amounts falling due within one year
2023
2022
£
£
Accruals and deferred income
900
900
Corporation tax
16,458
15,195
Director's loan account
3,998
2,997
-------------
-------------
21,356
19,092
-------------
-------------
7. Called up share capital
Issued, called up and fully paid
2023
2022
No.
£
No.
£
Ordinary shares of £ 1 each
2
2
2
2
-------------
-------------
-------------
-------------
8. Related party transactions
There is no one controlling party of the company. The director's loan account included in creditors is unsecured, repayable on demand and currently interest free.